1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy
Chemistry & Biodiversity · 2025-12 · 22 (12)
DOI: 10.1002/cbdv.202501361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, online erschienen am 26.08.2025. Verfasst von Pragya Gawande und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Discovery and Ecotoxicology, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh,…. Hauptthemen laut MEDLINE: Thiadiazoles, Vascular Endothelial Growth Factor Receptor-2, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 196 Literaturangaben.
Abstract (Originalsprache)
Vascular endothelial growth factor receptor‐2 (VEGFR‐2) plays a pivotal role in tumor angiogenesis, progression, and metastasis by modulating cell proliferation, migration, and survival via VEGF‐mediated signaling. Despite the therapeutic success of current VEGFR‐2 inhibitors, their clinical utility is often constrained by acquired resistance, off‐target toxicities, and suboptimal selectivity. The 1,3,4‐thiadiazole (TDA) scaffold has emerged as a privileged moiety in cancer drug discovery due to its mesoionic character, structural diversity, and molecular pharmacology. Notably, the ─N─N═C─S motif and sulfur atom of TDA significantly contribute to VEGFR‐2 binding through key molecular interactions. This work provides a comprehensive overview of the role of VEGFR‐2 in cancer biology, the chemistry of 1,3,4‐TDA, and the mechanistic basis of VEGFR‐2 inhibition. A systematic analysis of different publications from the last decade led to the extraction and evaluation of 151 TDA‐based VEGFR‐2 inhibitors. Chemical space, structure–activity relationship (SAR), substitution patterns, selectivity, toxicity, and essential binding interactions (ATP or allosteric site) with VEGFR‐2 were critically examined. The review underscores the potential of 1,3,4‐TDA derivatives as promising scaffolds for selective and efficacious VEGFR‐2 inhibition, offering strategic guidance for the rational design of next‐generation VEGFR‐2 inhibitors with improved efficiency, selectivity, and reduced toxicity for anticancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Drug Discovery and Ecotoxicology, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.
- Haldia Institute of Pharmacy, Haldia, West Bengal, India.
ORCID-Profile: Pragya Gawande, Balaji Wamanrao Matore, Anjali Murmu, Souranava Jana, Partha Pratim Roy, Jagadish Singh
Zitieren
APA
Gawande, P., Matore, B. W., Murmu, A., Kumar, A., Jana, S., Roy, P. P., & Singh, J. (2025). 1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy. Chemistry & Biodiversity, 22(12). https://doi.org/10.1002/cbdv.202501361
Vancouver
Gawande P, Matore BW, Murmu A, Kumar A, Jana S, Roy PP, et al. 1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy. Chemistry & Biodiversity. 2025;22(12). doi:10.1002/cbdv.202501361
BibTeX
@article{Gawande2025,
author = {Gawande, Pragya and Matore, Balaji Wamanrao and Murmu, Anjali and Kumar, Akshay and Jana, Souranava and Roy, Partha Pratim and Singh, Jagadish},
title = {1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy},
journal = {Chemistry & Biodiversity},
year = {2025},
volume = {22},
number = {12},
doi = {10.1002/cbdv.202501361}
}
EUVIMED